Mochi Health review
The rare compounded program that names its doctors and puts a real 30-minute video visit in front of the prescription — and then prices itself in two pieces, so the $99 on the front page is a little over half what leaves your account.
- Independently scored
- Verified
Every medical claim in this piece is footnoted to the record it came from — the trial or the FDA label — so you can read the source rather than take the masthead's word for it. No one on this desk is your clinician.
Mochi Health at a glance
- Semaglutide
- $178/mo all-in
- Tirzepatide
- $278/mo all-in
- Coverage
- All 50 states
- Brand-name
- Yes
How we scored Mochi Health
Each score comes out of Mochi Health's published pricing, disclosures and oversight, and the six combine into the 77/100 Editors' Rating on the same weighted six-factor framework we apply to every provider — never nudged by whether a provider pays us.
Fair value once you read past any teaser rate or plan structure.
Reasonable oversight, though some program details aren't fully public.
The headline rate obscures a plan requirement or a hidden step-up.
Little here is shaped around a mother's week or her life stage.
Standard support — enough to stay on track, not high-touch.
Leaving costs you — notice windows, minimum terms or fees you don't get back.
How we verified this review
- Last verified
- July 2026
- Confidence
- high
- Primary source
- www.joinmochi.com/faq
Two charges, not one. The $99 semaglutide price is real and flat across doses, but a $79 monthly clinic fee sits beside it, which makes the ongoing number $178 — and $278 for tirzepatide. The $138 and $238 on comparison tables are first-month totals built on a half-price clinic charge.
What to expect when you sign up
We walked Mochi Health's public signup funnel (July 2026) — a first-hand look at the flow. We don't create accounts, enter medical data, or complete checkout, so this is what any visitor sees, not a patient outcome.
- 1Both numbers are printed on the public weight-loss page before anything is asked — the clinic charge and the per-drug charge, side by side
- 2A short questionnaire builds the plan, then you choose a provider from a roster Mochi names in full on its about page
- 3A 30-minute video visit with that provider is scheduled; this is not an asynchronous intake you can finish at 11pm
- 4If a prescription follows, the medication is filled through what Mochi calls its Marketplace and billed on its own line
What we noticed
- The two charges are separate and the site states it plainly: 'Medications and diagnostic services not included in membership subscription'
- Drug pricing is flat — '$99/mo for all doses' semaglutide and '$199 for all doses' tirzepatide — so titrating up does not move the bill
- The '$39' on the front page is a half-price first month on the clinic charge alone; the standing rate is $79
- Nine clinicians are named with credentials, four of them board-certified in obesity medicine, alongside two registered dietitians
- No compounding pharmacy is named anywhere — the pharmacy page describes only a 'Mochi Marketplace' that patients and providers choose from
- Brand pens are named on the state pages (Ozempic, Wegovy, the Wegovy pill, Mounjaro, Rybelsus, Contrave) but no brand price is published
Pricing
Prices re-verified
| Medication | Monthly | Plan |
|---|---|---|
| Compounded semaglutide | $178 | All doses, all-in$79/mo for the clinic plus $99/mo for the drug at any dose. The first month of clinic access is half price ($39), so month one lands at $138 and every month after at $178. |
| Compounded tirzepatide | $278 | All doses, all-in$79/mo for the clinic plus $199/mo for the drug at any dose. Month one is $238 on the half-price offer, then $278. |
| Compounded semaglutide | $166 | All doses, twelve months paid upfront$799 buys twelve months of clinic access (about $67/mo); the $99 drug charge is unchanged. Six months is $399 and three months $199. |
| Compounded tirzepatide | $266 | All doses, twelve months paid upfrontThe same upfront clinic rate carrying the $199 tirzepatide charge. |
Swipe the table to see plan details →
GLP-1 telehealth is usually HSA- and FSA-eligible, so check your own plan. Everything above comes from Mochi Health's public disclosures at last review and change often; confirm the current number on Mochi Health's own site.
What we like
- Nine clinicians named with credentials, five of them carrying obesity-medicine board certification, plus two registered dietitians
- A 30-minute video visit with a provider you choose — most of this roster never puts you in front of anyone
- Drug pricing is genuinely flat across every dose, so titrating toward a full dose does not raise the bill
- Every price is public before the intake, and the site says outright that medication is not covered by the monthly clinic charge
- Nationwide, with brand pens (Ozempic, Wegovy, Mounjaro, Rybelsus) named alongside the compounded line
The caveats
- Two charges, not one: the advertised $99 becomes $178 a month once the $79 clinic fee is added, and $278 for tirzepatide
- The widely quoted $138 and $238 figures are first-month prices on a half-price promo, not the ongoing rate
- No compounding pharmacy is named anywhere — the pharmacy page describes only an unnamed 'Marketplace'
- Eli Lilly and Novo Nordisk both have pending federal suits over the compounded line, plus a 2026 consumer class action
- The required video visit is real care but also a scheduled appointment, which is the scarcest thing a mother has
- No postpartum, breastfeeding or PCOS guidance, and no brand-name price published anywhere
Mochi Health: the $99 on the front page is about half the bill
Mochi advertises compounded semaglutide at $99 a month, flat at every dose, and that figure is true. It is also only one of the two charges. The clinic itself costs $79 a month, and Mochi says so in a single unambiguous line on its own weight-loss page: medications and diagnostic services are not included in the membership. Add the two together and the real ongoing cost is $178 a month for semaglutide and $278 for tirzepatide — a little under the ~$179 median this masthead tracks, but forty dollars a month above what a comparison table will tell you. The first month looks cheaper still, because the clinic charge is halved to $39, which is where the $138 and $238 figures circulating elsewhere come from. Both are month-one prices wearing a monthly label.
We are being precise about this because the two-part structure is the single most common way a family budget gets ambushed in this market, and because Mochi, to its credit, is not hiding it. The disclosure is right there. It is just printed next to a $99 that is set in much larger type.
What the money actually buys
- Compounded semaglutide: $178/month all-in — $79 clinic, $99 drug, flat at every dose
- Compounded tirzepatide: $278/month all-in — $79 clinic, $199 drug, also flat at every dose
- First month: $138 or $238, on a half-price clinic charge that does not repeat
- Paid ahead: $199 for three months of clinic access, $399 for six, $799 for twelve — the drug charge is unchanged either way
- Not included: the medication, any diagnostics, and any brand-name pen, for which no price is published at all
The clinical bench is the reason to look twice
Most of the compounded field on this masthead is anonymous. You fill in a form, someone with a license approves it, and you never learn a name. Mochi does the opposite: it lists nine clinicians with credentials attached — Roberto Valledor MD, Leah Jones MD, Clete Barrick MD, Amisa Patel DO and Amber Patel DO among them, carrying obesity-medicine board certification between them, plus a pediatrician, a nurse practitioner and two registered dietitians. Then it puts a 30-minute video visit with the provider you pick in front of the prescription. Not an asynchronous review. An appointment, with a person, who has trained in the specific medicine you are asking about.
For a mother that cuts both ways, and it is worth being honest about the second edge. Thirty minutes on video with an obesity-medicine physician is a genuinely better standard of care than a questionnaire, and it is the kind of thing that catches a thyroid history or a pregnancy plan that a form would sail past. It is also thirty minutes you have to find, at a time you have to agree to, which is the scarcest currency a mother has. If asynchronous is the only way a program fits your week, that is a real constraint and not a preference.
The gap in the disclosure, and the two companies in court
For all the names Mochi publishes, one is missing: the pharmacy. Its terms refer only to "certain third party pharmacies" and its pharmacy page describes a marketplace that patients and providers choose from, without naming a single one. For a compounded medication — a preparation that is not an FDA-approved finished product the way Wegovy and Zepbound are — the compounder's identity is the disclosure that matters most, and it is the one you cannot check. Providers like Trimi Health name theirs. Mochi does not.
The second thing to know is that both manufacturers have taken Mochi to federal court over its compounded line. Eli Lilly filed in the Northern District of California in April 2025 and Novo Nordisk followed in August 2025; a consumer class action was filed in the same court in February 2026. All three are pending, and an allegation is not a finding — plenty of telehealth compounders are facing near-identical suits as the shortage-era compounding window closes. But it is the kind of fact you would rather learn now than from a letter telling you your prescription has stopped.
What it does not offer a mother
Nothing maternal, and this is where a strong clinical program still reads as a general one. There is no postpartum guidance, no breastfeeding guidance and no PCOS pathway anywhere on the site; menopause and hormone therapy exist, but as a separate vertical you buy separately. As with every GLP-1, none of this is for use during pregnancy or while breastfeeding, and every label says so. What Mochi gives you is an obesity-medicine physician on a video call who is qualified to have that timing conversation — you will simply have to raise it yourself, because the site never will. Our guide on what to tell your OB before starting a GLP-1 is the conversation to have first.
The bottom line
Mochi Health is a better-run program than its pricing presentation suggests, and a more expensive one. Budget $178, not $99, and you are buying a named, board-certified clinician and a real appointment for roughly the market rate — which is a fair trade, and rare. Hold against it the unnamed pharmacy and two manufacturers in court. If what you want instead is one number that is the whole number, with a prescriber who raises pregnancy and weaning without being asked, our #1 pick, CoreAge Rx, is the cleaner fit — you can put the two side by side in our head-to-head or against the field in the best GLP-1 for moms ranking.
The bottom line for mothers
Best for: Mothers who want a named, board-certified obesity-medicine clinician and an actual appointment rather than a form, and who will do the arithmetic on the two-part bill before signing up.
Alternatives to Mochi Health
Providers we have a referral relationship with, ordered by their Editors' Rating — highest first. A fee never moves a rating, but it does decide who appears here, so this is not the whole roster: the full ranking lists every provider we cover.
- Visit CoreAge RxCoreAge RxOur #1 pick
The one program on this masthead whose number still makes sense at the top of the dose. A flat, all-in monthly price on both molecules, no teaser rate to expire, and a cancel button you can actually find — the closest thing to a family-budget guarantee we've reviewed.
- Visit Gala Health
A flat $179 for either molecule and a genuinely gentle microdosing tier — a reasonable, all-doses-included option, if you can live with a yearly plan and a pharmacy the marketing never names.
- Visit Sesame
A high-trust telehealth marketplace that took a clear side: FDA-approved brand GLP-1 only, no compounded shortcut. You pay a brand cash price and book a real video visit — but you get on-label pens and one of the cleaner reputations on this masthead.
Keep comparing Mochi Health
Head-to-head & alternatives
Mochi Health, answered
- Is Mochi Health really $99 a month?
- No — $99 is what the compounded semaglutide costs, and it is only half the bill. Mochi charges $79 a month for the clinic itself and says outright that 'medications and diagnostic services' are not covered by it. The real ongoing figure is $178 a month for semaglutide and $278 for tirzepatide. The first month looks cheaper because the clinic charge is halved to $39, which is where the $138 and $238 numbers on comparison tables come from; both are month-one prices being passed off as the monthly rate. Budget the second month, not the first.
- Does Mochi Health serve my state?
- Almost certainly. Mochi's FAQ says its services are reachable 'from anywhere in the United States' and its about page describes operations across all 50 states. You may see a figure of fifteen states quoted elsewhere; that is the number of state-specific pages Mochi has built for search, not a limit on where it practices. What does vary by state is the promotional pricing, which Mochi footnotes as not available everywhere.
- Who actually prescribes at Mochi, and does anyone see me?
- This is Mochi's strongest card. It names its clinicians in full — five physicians carrying obesity-medicine board certification among them, a pediatrician, a nurse practitioner and two registered dietitians — and it requires a 30-minute video visit with the provider you choose rather than an intake form a clinician skims. On a roster where most compounded programs are asynchronous and anonymous, being able to read the name and the credential before you pay is worth something. What Mochi does not name is the pharmacy compounding the medicine, which is the disclosure a compounded program most needs to make.
- Is there anything a mother should weigh before signing up?
- Two things beyond the price. First, no compounding pharmacy is named anywhere on the site — the pharmacy page describes a marketplace of unnamed partners — so you cannot check who is making the drug. Second, both manufacturers have taken Mochi to federal court over its compounded line: Eli Lilly filed in April 2025 and Novo Nordisk in August 2025, both in the Northern District of California, and a consumer class action followed in February 2026. All three are pending, and allegations are not findings — but they are the kind of thing worth knowing before you commit a card. As with every GLP-1, none of this is for use during pregnancy or breastfeeding, and Mochi publishes no postpartum or PCOS guidance to help you plan the timing.
Pricing, states and verification reflect Mochi Health's public disclosures at last review; the Editors' Rating is our editorial judgment per the published methodology. This is background reading, not medical advice — GLP-1 medications are not established as safe in pregnancy or breastfeeding. See our medical disclaimer and how we're funded.